MedTrace Logo

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

NCT07502560 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33609

Last updated 2026-05-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

Recombinant zoster vaccine

Recombinant zoster vaccine administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose), according to the approved recombinant zoster vaccine dosing schedule.

DRUG

Placebo

Placebo administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose).

Sponsors & Collaborators

  • Finnish Vaccine Research;

    collaborator UNKNOWN

  • Dr Arto Palmu

    collaborator UNKNOWN

  • GlaxoSmithKline

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
76 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2030-04-01
Completion
2037-03-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07502560 on ClinicalTrials.gov